The contracts are for two lateral flow rapid antigen tests, a laboratory-based test to detect and identify SARS-CoV-2 variants, and a rapid RT-PCR test.
The firm's test reader can be attached to any smartphone to take images of the test results and send them to be interpreted by artificial intelligence.
While the human toll of the disease has been terrible, IVD makers also report there have been some positive developments, as demand has spiked and familiarity with testing has grown.
The lateral flow test is designed to detect immunoglobulin G antibodies against SARS-CoV-2 in a finger prick blood sample and returns results in 20 minutes.
The kit, developed by Gauss in collaboration with Cellex, uses a smartphone app to instruct an individual on how to collect a sample and perform the test.
